Ticagrelor-d7

• Catalog No.: T437702
• M. F.: C23H28F2N6O4S
• M. W.: 522.5680264

SYNONYMS

• IUPAC name: (1S,2S,3R,5S)-3-(7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-[(^2H₇)propylsulfanyl]-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
• IUPAC Traditional name: (1S,2S,3R,5S)-3-(7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-[(^2H₇)propylsulfanyl]-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol
• Synonyms: (1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-D1,2-Cyclopentanediolifluorophenyl)cyclopropyl]amino]-5-(propylthio-d7)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol; AR-C 126532XX-d7; AZD 6140-d7

DETAILS

Description (English)

Labelled Ticagrelor (T437700), the first reversible oral P2Y12 receptor antagonist, provides faster, greater, and more consistent ADP-receptor inhibition than Clopidogrel. Used in the treatment of acute coronary syndromes (ACS).

REFERENCES

• Matetzky, S., et al.: Circulation, 109, 3171 (2004)
• Bassand, J., et al.: Eur. Heart J., 28, 1598 (2004)
• Jakubowski, J., et al.: Cardiovasc. Drug Rev., 25, 357 (2004)